Disclaimer: PBS listings change frequently. Eligibility criteria, co-payment amounts, and prescriber restrictions are subject to ongoing PBAC review. Always verify the current status of any medication with your GP or the PBS website before making health or financial decisions.
Australia's Pharmaceutical Benefits Scheme has historically provided almost nothing for obesity, effective medications existed, but none were PBS-listed, leaving Australians to pay $350 to $500 per month out of pocket or go without treatment. That began to change in November 2025, when the PBAC recommended Wegovy (semaglutide 2.4 mg weekly injectable) for PBS listing, the first positive recommendation for an obesity-specific medication. The listing itself has not yet taken effect: price negotiations between the government and the manufacturer are ongoing, and the listing is expected around mid-2026. Once it takes effect, standard PBS co-payments would cut monthly costs to under $32 for general patients and under $8 for concession card holders.
The recommendation also carries symbolic weight: it represents formal recognition that obesity is a chronic medical condition deserving subsidised treatment on the same footing as type 2 diabetes or cardiovascular disease. This article covers where each medication stands, who is expected to qualify, and what the pipeline looks like through 2027.
Understanding the sparse history of PBS obesity listings requires a grasp of Australia's two-stage pharmaceutical approval process.
TGA approval establishes that a medication is sufficiently safe and effective to be sold in Australia. This is necessary but not sufficient for PBS subsidy. A drug can hold TGA approval and remain unavailable on the PBS indefinitely, Saxenda being the obvious example after a decade on the Australian market without a subsidised listing.
PBAC evaluation is the separate economic and clinical hurdle. The Pharmaceutical Benefits Advisory Committee reviews manufacturer-submitted dossiers comparing a new medication's cost-effectiveness against the existing standard of care. If PBAC recommends listing, the federal government negotiates a price with the manufacturer and formally adds the medication to the PBS schedule.
For obesity medications specifically, PBS listings come with Authority Required prescriptions. Prescribers cannot issue a standard script, they must apply to Services Australia confirming the patient meets specified eligibility criteria. This gatekeeping ensures subsidised access is confined to the clinical population PBAC determined to be cost-effective.
The gap between TGA approval and PBS listing can span years. Companies choose when to submit PBAC dossiers, and PBAC may request additional data or reject submissions outright.
Wegovy is not yet PBS-listed. It is, however, the only obesity-specific medication holding a positive PBAC recommendation: the committee recommended it for listing at its November 2025 meeting, and the listing is expected to take effect around mid-2026 once price negotiations conclude. Key details:
Recommended eligibility: The PBAC recommendation covers a narrower population than the TGA indication: adults with established cardiovascular disease AND obesity, defined as BMI of 35 or above, or 32.5 or above for people of Asian, Aboriginal or Torres Strait Islander background. It is not a general weight-management listing, and it does not extend to the broader BMI-30-plus-comorbidity population. Final criteria are confirmed at gazette listing.
Projected PBS co-payments:
Once the listing takes effect, these standard co-payments would represent a reduction from the $400 to $500 per month private cost that applies in the meantime.
Prescriber access: Obesity medication listings are expected to carry Authority Required restrictions. Final prescriber arrangements, including whether initiation is restricted to specialists, will be confirmed when the listing takes effect.
Continuation criteria: Any continuation requirements, such as demonstrating a minimum weight-loss response at review, will also be confirmed at listing. Until Wegovy is listed, all prescriptions are private.
Ozempic uses the same active ingredient as Wegovy (semaglutide) but at lower doses and with a PBS listing restricted to type 2 diabetes management. It is not PBS-listed for obesity.
The patient overlap is significant, many individuals with obesity also carry a T2DM diagnosis, meaning Ozempic prescribed for glycaemic control delivers meaningful weight loss as a secondary benefit. Prescribers and patients should be clear, however, that using Ozempic for weight loss outside a diabetes indication does not satisfy PBS criteria and requires a private script; once Wegovy's pending obesity listing takes effect, eligible patients would instead apply under that separate Authority pathway.
Saxenda (liraglutide 3 mg) remains off the PBS despite holding TGA approval for chronic weight management. Private cost sits at approximately $350 to $500 per month.
With Wegovy approaching PBS listing and demonstrating superior weight loss outcomes in head-to-head comparisons, Saxenda's commercial position has weakened considerably. Novo Nordisk has not pursued a PBAC submission for Saxenda's obesity indication in Australia, and with tirzepatide approaching the market, a PBS listing for liraglutide in this indication is unlikely to materialise.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with weight loss efficacy that exceeds semaglutide in head-to-head comparisons. Eli Lilly markets it under two names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Mounjaro is TGA-approved in Australia for T2DM. Zepbound's TGA pathway for the obesity indication is progressing. Neither currently carries a positive PBAC recommendation for the obesity indication. A PBAC submission is anticipated.
The SURMOUNT trial programme produced some of the most striking weight loss data recorded in obesity pharmacotherapy. At the 15 mg weekly maintenance dose, participants lost approximately 22% of body weight on average over 72 weeks, substantially above the approximately 15% observed with semaglutide 2.4 mg in the STEP trials.
A PBAC submission for Zepbound in the obesity indication is anticipated. Given the efficacy data, the cardiovascular outcomes evidence accumulating in this drug class, and the precedent Wegovy's PBAC recommendation has set, a positive PBAC recommendation is a realistic expectation, with a PBS listing to follow depending on price negotiation pace. Eligibility criteria would be settled through the same PBAC process and, on the Wegovy precedent, could be similarly targeted rather than covering all adults with obesity.
Rybelsus is the oral tablet formulation of semaglutide, PBS-listed for type 2 diabetes at 7 mg and 14 mg doses. The lower doses and oral delivery route produce more modest weight loss than Wegovy's injectable 2.4 mg regimen. Novo Nordisk has not pursued a PBS obesity indication for this formulation, and no obesity-dose oral semaglutide pathway is expected in the near term.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, a mechanism that appears to deliver additive metabolic benefits beyond dual or single agonism. Phase 2 data showed average body weight reductions of approximately 24% at 48 weeks, the highest pharmacological weight loss figures recorded to date. Phase 3 trials are underway.
A TGA submission and any subsequent PBAC evaluation would realistically fall into a later window. Retatrutide represents a meaningful horizon for Australian patients, but it is not an imminent access story.
The recommended criteria (established cardiovascular disease plus BMI of 35 or above, or 32.5 or above for people of Asian, Aboriginal or Torres Strait Islander background) leave most Australians with obesity without a subsidised pathway. A person with BMI of 32, or one with BMI of 38 but no established cardiovascular disease, would not qualify despite sitting within the clinical obesity range. The SELECT cardiovascular outcomes trial, which enrolled participants from BMI 27, strengthens the case for eventually broadening thresholds, but PBAC cost-effectiveness modelling at initial listing tends to be conservative.
The practical implication: eligibility hinges on documented cardiovascular disease alongside BMI. If you have a cardiovascular history that has not been formally diagnosed and coded in your records, that conversation with your GP is worth having before concluding you won't meet criteria once the listing takes effect.
GLP-1 medications experienced widespread global supply shortages from 2023 through mid-2025 as demand outpaced manufacturing capacity. In Australia, the TGA activated provisions allowing compounding pharmacies to produce semaglutide and tirzepatide under declared shortage conditions, a regulatory grey zone that served as a stopgap.
As brand supply stabilised through late 2025, TGA moved to tighten compounding rules. Patients currently accessing compounded GLP-1s should expect that pathway to close or become materially restricted through 2026, making PBS access to brand medications, once Wegovy's listing takes effect, the primary affordable route for qualifying patients.
| Access Route | Approximate Monthly Cost | Key Considerations |
|---|---|---|
| PBS Wegovy, concession (projected, once listed) | ~$7.70 | Listing pending, expected around mid-2026 |
| PBS Wegovy, general patient (projected, once listed) | ~$31.60 | Authority Required; CV disease plus obesity criteria |
| Private Saxenda | ~$350–500 | TGA approved, no PBS subsidy |
| Private Wegovy (current route until listing) | ~$400–500 | Full private cost |
| Compounded semaglutide (domestic) | ~$80–180 | Regulatory status tightening through 2026 |
| Offshore/medical tourism sourcing | ~$50–150 | Significant risks, see below |
The offshore route carries risks the cost comparison doesn't capture: cold chain integrity cannot be verified, dosing accuracy is unconfirmed, and there is no prescribing oversight or regulatory recourse. For patients who don't meet PBS criteria, supervised access through a prescriber remains the safer path even at private cost.
One of the most clinically important findings from long-term GLP-1 trials is what happens when treatment stops. The STEP 4 withdrawal trial found that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year of stopping. Cardiometabolic markers (blood pressure, blood glucose, lipid levels) also drifted back toward pre-treatment baselines.
This has practical implications for PBS policy. Obesity medicine specialists increasingly frame GLP-1 medications the same way as antihypertensives or statins: not a fixed course with a defined endpoint, but ongoing treatment for a chronic condition. If Wegovy's eventual listing carries continuation criteria involving periodic reviews, that could create friction for patients who need indefinite therapy.
Weight regain after stopping is not a personal failure. It reflects the chronic neurobiology of obesity, where the body defends its pre-treatment weight through hormonal adaptation. Having a clear long-term plan, including financial contingency if PBS criteria change, is worth discussing at the point of initiation.
Step 1, Consult your GP. Bring your current height and weight, recent blood pressure readings, and any pathology results on file. Be ready to discuss your weight history and any comorbidities.
Step 2, Document eligibility. Your GP will calculate your BMI and assess whether you have established cardiovascular disease that is formally diagnosed and coded, the anchor of the recommended criteria. If a cardiovascular history is present but undocumented, formalising that diagnosis may change your eligibility once the listing takes effect.
Step 3, Authority prescription (once listed). When the listing takes effect, expected around mid-2026, your GP applies for Authority through Services Australia if you meet the final criteria. Until then, Wegovy is available only on a private prescription at full cost. Telehealth obesity medicine services have expanded access in regional areas.
Step 4, Titration. Wegovy starts at 0.25 mg weekly and increases gradually over approximately 16 to 20 weeks to the 2.4 mg maintenance dose. Gastrointestinal side effects are most common during escalation and typically improve as the body adjusts.
Step 5, Ongoing review. Expect periodic reviews of response and tolerability; any formal PBS continuation requirements will be confirmed when the listing takes effect. Reviews are also an opportunity to assess tolerability, adjust the titration timeline if needed, and plan for ongoing management.
Throughout this process, lifestyle modification (dietary quality, sleep, movement) accompanies pharmacotherapy rather than being replaced by it. For those interested in the mechanism science and emerging compound research underpinning this class, GLP-1 peptide research continues to advance rapidly.
Australia's PBS landscape for obesity treatment is shifting materially with Wegovy's November 2025 PBAC recommendation, the first for an obesity-specific medication. The listing has not yet taken effect: it is expected around mid-2026 once price negotiations conclude, and would reduce monthly costs from several hundred dollars to under $32 for qualifying patients. Recommended eligibility covers adults with established cardiovascular disease and obesity (BMI of 35 or above, or 32.5 or above for people of Asian, Aboriginal or Torres Strait Islander background), accessed through an Authority Required prescription process.
Tirzepatide (Zepbound) is the next meaningful milestone. With SURMOUNT trial data showing approximately 22% average weight loss and a PBAC submission anticipated, an Australian PBS listing in a subsequent window is a realistic expectation. Retatrutide, with phase 3 trials showing approximately 24% average weight loss, extends the pipeline into 2027 and beyond.
For Australians who expect to meet the recommended criteria, PBS-subsidised access to Wegovy is a genuine clinical opportunity at a cost that is genuinely accessible. For those who don't quite qualify, the criteria are worth re-examining with a GP, particularly where cardiovascular disease may be present but not yet formally documented.
Co-payment figures cited reflect 2026 PBS general and concession rates and are subject to annual indexation. Verify current costs at pbs.gov.au. Eligibility criteria are based on PBAC recommendations and published guidelines; final criteria for any listed medication are confirmed at gazette listing. This article is for educational purposes only and does not constitute medical advice.
Emerging research on GLP-1 receptor agonists and alcohol cravings: 2025 RCT data, the reward-pathway mechanism, and what it means for semaglutide users.
Comparing bariatric surgery and GLP-1 medications on efficacy, durability, cost, and risk in Australia today, plus a practical decision framework for 2026.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.